Generic Brilinta Availability
Last updated on Apr 10, 2025.
Brilinta is a brand name of ticagrelor, approved by the FDA in the following formulation(s):
BRILINTA (ticagrelor - tablet;oral)
-
Manufacturer: ASTRAZENECA
Approval date: July 20, 2011
Strength(s): 90MG [RLD] [AB] -
Manufacturer: ASTRAZENECA
Approval date: September 3, 2015
Strength(s): 60MG [RLD] [AB]
Is there a generic version of Brilinta available?
A generic version of Brilinta has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Brilinta and have been approved by the FDA:
ticagrelor tablet;oral
-
Manufacturer: ALKEM LABS LTD
Approval date: April 21, 2023
Strength(s): 90MG [AB] -
Manufacturer: DR REDDYS
Approval date: October 29, 2024
Strength(s): 90MG [AB] -
Manufacturer: HISUN PHARM HANGZHOU
Approval date: January 23, 2019
Strength(s): 90MG [AB] -
Manufacturer: MSN
Approval date: April 7, 2020
Strength(s): 90MG [AB] -
Manufacturer: PRINSTON INC
Approval date: August 16, 2024
Strength(s): 90MG [AB] -
Manufacturer: SUNSHINE
Approval date: April 6, 2020
Strength(s): 90MG [AB] -
Manufacturer: WATSON LABS INC
Approval date: September 4, 2018
Strength(s): 60MG [AB], 90MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brilinta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Patent 10,300,065
Issued: May 28, 2019
Inventor(s): Andersson Lars Magnus & Andersson Tomas Lars-Gunnar & Bengtsson Olof Fredrik & Held Hans Peter & Howells Garnet Edward & Jensen Eva Christina & Storey Robert
Assignee(s): ASTRAZENECA ABThe present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
Patent expiration dates:
- January 27, 2036✓
- January 27, 2036✓
- January 27, 2036
-
Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Patent 10300065*PE
Issued: May 28, 2019
Inventor(s): Andersson Lars Magnus & Andersson Tomas Lars-Gunnar & Bengtsson Olof Fredrik & Held Hans Peter & Howells Garnet Edward & Jensen Eva Christina & Storey Robert
Assignee(s): ASTRAZENECA ABThe present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
Patent expiration dates:
- July 27, 2036
- July 27, 2036
-
Pharmaceutical compositions
Patent 8,425,934
Issued: April 23, 2013
Inventor(s): Banks Simon
Assignee(s): AstraZeneca ABThe present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Patent expiration dates:
- April 17, 2030✓
- April 17, 2030
-
Pharmaceutical compositions
Patent 8425934*PED
Issued: April 23, 2013
Inventor(s): Banks Simon
Assignee(s): AstraZeneca ABThe present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Patent expiration dates:
- October 17, 2030✓
- October 17, 2030
-
Triazolo(4,5-D)pyrimidine compounds
Patent RE46276*PED
Issued: January 17, 2017
Inventor(s): Hardem David & Ingall Anthony & Springthorpe Brian & Willis Paul & Guile Simon
Assignee(s): AstraZeneca UK LimitedTriazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows:
Patent expiration dates:
- April 30, 2025✓
- April 30, 2025
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 9, 2025 - INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HESTIA3
- November 9, 2025 - PEDIATRIC EXCLUSIVITY
More about Brilinta (ticagrelor)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (101)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: platelet aggregation inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.